Leadership Overview
Fresenius Kabi has 7 executives leading key functions including financial strategy, operational management, medical technology, and pharmaceutical development.
Committed to advancing patient care through infusion and clinical nutrition, Fresenius Kabi delivers essential medicines and technologies to healthcare providers across global markets.
Committed to advancing patient care through infusion and clinical nutrition, Fresenius Kabi delivers essential medicines and technologies to healthcare providers across global markets.
Leadership Roles at Fresenius Kabi
Richard Tajak - Chief Financial Officer
Richard Tajak, the Chief Financial Officer at Fresenius Kabi, directs all global fiscal planning and capital allocation strategies. Overseeing the financial health of the infusion and clinical nutrition divisions, the Chief Financial Officer ensures rigorous compliance with international accounting standards. This leadership role involves managing complex budgetary frameworks to support the development of life-saving medical technologies. By optimizing resource distribution across diverse manufacturing sites, Richard Tajak directly impacts the long-term profitability and stability of the organization. The Chief Financial Officer maintains close collaboration with the board to align fiscal objectives with the broader mission of improving patient outcomes. Through disciplined oversight of capital expenditures, Tajak secures the necessary funding for research and development initiatives, ultimately strengthening the market position of the company within the competitive pharmaceutical landscape.
Alex Garini - Executive Vice President & Chief Financial Officer
Alex Garini, the Executive Vice President & Chief Financial Officer at Fresenius Kabi, architects the overarching financial strategy and investment roadmap for the global enterprise. Overseeing corporate finance, treasury, and investor relations, the Executive Vice President & Chief Financial Officer ensures the financial resilience of the infusion and transfusion business units. This leadership role involves evaluating strategic acquisitions and partnerships to expand the company footprint in the pharmaceutical sector. By providing analytical insights into market trends, Alex Garini directly influences the long-term growth trajectory and shareholder value. The Executive Vice President & Chief Financial Officer collaborates with regional leaders to manage financial risks associated with international operations. Through meticulous financial planning and performance monitoring, Garini supports the sustainable delivery of innovative healthcare solutions, ensuring the organization remains at the forefront of clinical nutrition and medical technology.
Christian Mattis - Chief Financial Officer, Medtech NAM
Christian Mattis, the Chief Financial Officer, Medtech NAM at Fresenius Kabi, manages the financial operations for the medical technology division within the North American market. Overseeing regional budgeting and financial reporting, the Chief Financial Officer, Medtech NAM ensures the profitability of infusion and transfusion technology deployments. This leadership role involves analyzing regional market data to optimize pricing strategies and cost structures for medical devices. By aligning financial goals with North American operational needs, Christian Mattis directly supports the expansion of the company technology portfolio. The Chief Financial Officer, Medtech NAM works closely with regional sales and product teams to drive revenue growth and operational efficiency. Through rigorous financial oversight and strategic planning, Mattis secures the resources required to maintain a competitive edge in the North American healthcare sector, ensuring consistent performance across the region.
Kaushal Gupta - Chief Financial Officer, of Fresenius Kabi (South, Asia, India)
Kaushal Gupta, the Chief Financial Officer, of Fresenius Kabi (South, Asia, India) at Fresenius Kabi, directs the financial strategy for the South Asian and Indian markets. Overseeing regional fiscal compliance and local investment initiatives, the Chief Financial Officer, of Fresenius Kabi (South, Asia, India) ensures the financial viability of infusion and clinical nutrition operations in these high-growth regions. This leadership role involves navigating complex regulatory environments and currency fluctuations to maintain stable profit margins. By providing localized financial guidance, Kaushal Gupta directly supports the expansion of the company presence across South Asia and India. The Chief Financial Officer, of Fresenius Kabi (South, Asia, India) collaborates with regional management to optimize supply chain costs and distribution efficiency. Through strategic financial management, Gupta facilitates the delivery of essential healthcare products to diverse patient populations, driving growth in these critical emerging markets.
Rakesh Patel - Chief Operating Officer
Rakesh Patel, the Chief Operating Officer at Fresenius Kabi, manages the end-to-end supply chain and manufacturing excellence for infusion and transfusion products. Overseeing global production facilities, the Chief Operating Officer drives operational efficiency and quality control protocols to meet stringent healthcare standards. This leadership role involves coordinating cross-functional teams to streamline logistics and distribution networks across international markets. By implementing advanced manufacturing technologies, Rakesh Patel directly enhances the production capacity and reliability of essential clinical nutrition supplies. The Chief Operating Officer works alongside executive leadership to scale operations in response to fluctuating global demand. Through continuous process improvement and lean management strategies, Patel ensures the seamless delivery of critical medical solutions to hospitals and clinics worldwide, maintaining the high standards expected of the organization.
Takaaki Okado - Representative Director and President
Takaaki Okado, the Representative Director and President at Fresenius Kabi, leads the strategic direction and corporate governance for the organization. Overseeing the alignment of global business units with the core mission of providing infusion and clinical nutrition solutions, the Representative Director and President ensures the company maintains its commitment to patient care. This leadership role involves setting long-term objectives and fostering a culture of innovation across all departments. By engaging with stakeholders and the board, Takaaki Okado directly shapes the market impact and reputation of the company. The Representative Director and President coordinates with executive leadership to address global healthcare challenges and identify new opportunities for growth. Through visionary leadership and a focus on operational excellence, Okado drives the organization toward achieving its strategic goals, ensuring the continued delivery of high-quality medical products to healthcare providers worldwide.
Scott Meacham - President, Pharmaceuticals (USA)
Scott Meacham, the President, Pharmaceuticals (USA) at Fresenius Kabi, directs the commercial strategy and market execution for the pharmaceutical division within the United States. Overseeing the development and distribution of infusion and clinical nutrition products, the President, Pharmaceuticals (USA) ensures the company meets the needs of the American healthcare system. This leadership role involves managing relationships with key healthcare providers and navigating the competitive landscape of the US pharmaceutical market. By driving sales growth and product adoption, Scott Meacham directly contributes to the overall success of the organization in North America. The President, Pharmaceuticals (USA) collaborates with internal teams to ensure the timely delivery of essential medicines and technologies. Through strategic market positioning and a focus on customer needs, Meacham strengthens the presence of the company in the US, supporting the broader mission of improving patient outcomes.
Explore Leadership Teams in Manufacturing
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas. The company focuses on areas such as oncology, internal medicine, inflammation and immunology, and vaccines to help prevent, treat, and manage disease worldwide.
Company Leadership SC
SK
NA
MO
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Company Leadership MB
SB
JP
SM
Shionogi & Co., Ltd. is a Japanese pharmaceutical company dedicated to developing innovative treatments that improve patient lives worldwide. With a longstanding focus on addressing pressing global health challenges, the company has been a pioneer in discovering and delivering novel therapies for infectious diseases, including antibiotics, HIV, influenza, and emerging viral threats such as COVID-19. Shionogi combines in-house research and development with strategic collaborations across industry, government agencies, biotech companies, and academic institutions to accelerate the advancement of its scientific programs and bring meaningful therapies to patients with urgency and precision.
Company Leadership TK
TN
MF
OneSource Specialty Pharma Limited is a multimodal specialty pharmaceutical contract development and manufacturing organization headquartered in Bengaluru, India. Formed through the merger of three CDMO businesses within the Strides Group, specifically Stelis Biopharma's Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatin businesses, OneSource was officially launched at CPHI Milan in 2024. The company operates five state-of-the-art manufacturing facilities in Bengaluru, all approved by major regulatory bodies including the US FDA, European Union authorities, and the Therapeutic Goods Administration. With over 30 years of manufacturing and quality excellence, OneSource employs more than 1,200 professionals, including over 200 techno-commercial experts, and serves more than 50 global pharmaceutical and biotechnology clients. The company specializes in end-to-end capabilities across multiple technology platforms and therapeutic modalities, including biologics drug substance and drug product manufacturing, drug-device combinations such as prefilled syringes and autoinjectors, complex sterile injectables, and soft gelatin capsules. OneSource has the capacity to produce over 100 million injectable doses and 2.4 billion soft gelatin capsules annually, with its flagship Bangalore site being one of the few facilities globally capable of manufacturing both biologics drug substance and drug product on the same premises. The company holds 35 approved Abbreviated New Drug Applications and has 19 commercialized drug products in the United States. Led by CEO Neeraj Sharma and Chief Quality Officer Bernhard Thurnbauer, OneSource is positioned to capitalize on growing demand for GLP-1 drug-device combinations and supply chain diversification driven by the BIOSECURE Act, projecting 32 percent revenue growth in 2025 with sales expected to reach 400 million dollars by 2028.
Company Leadership NS
SN
BM
Frequently Asked Questions Regarding Fresenius Kabi Top Executives and Leadership Team
Unlock more people and company data
